Compare Howmet Aerospace Inc (HWM) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Incyte Corporation — how do they compare? Howmet Aerospace Inc trades at $280.7 (market cap $111.63B), while Incyte Corporation trades at $115.81 (market cap $23.44B). The key difference: Howmet Aerospace Inc is far larger — about 4.8× Incyte Corporation's market cap, and Howmet Aerospace Inc pays a 0.17% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| HWM | INCY | |
|---|---|---|
Market Cap | $111.63B | $23.44B |
Sector | Industrials | Health |
52-Week High | $283.23 | $118.52 |
52-Week Low | $171.00 | $68.90 |
Enterprise Value | $113.88B | $19.46B |
Dividend Yield | 0.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $271.98, down 0.17% on the day, with technical indicators showing a neutral trend. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.22 beating expectations of $1.11, and robust profitability with a 20.22% net income margin. Recent news highlights strength in commercial aerospace demand driving growth prospects.
The outlook remains positive with 84% analyst buy ratings and a $317.63 consensus price target implying 17% upside. Key risks include premium valuation multiples and exposure to aerospace cycle volatility. Continued execution on commercial aerospace growth and defense contracts supports the bullish case, though investors should monitor Q2 2026 earnings due August 6 for confirmation.
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
